[ad_1]
HANGZHOU, China and SHAOXING, China, March 13, 2022 /PRNewswire/ — Ascletis Pharma Inc. (Ascletis, HKEX: 1672) today announces that it has further expanded its ritonavir oral tablet production capacity to approximately 530 million tablets per year, to meet the potential escalation in the domestic and global demands. Ascletis has taken multiple measures for expansion of the annual ritonavir production capacity, including adding additional key equipment at the manufacturing facilities of Ascletis Pharmaceuticals Co., Ltd., a wholly-owned subsidiary of Ascletis.
Ritonavir oral tablet is a pharmacokinetic booster of multiple oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug PAXLOVID (Nirmatrelvir 300 mg tablet + ritonavir 100 mg tablet co-administration package).
Ascletis aims to be a global commercial supplier of ritonavir oral tablets. To date, Ascletis owns the only authorized ritonavir oral tablet in China, which has passed bioequivalence study. Ascletis’ ritonavir oral tablet was approved in September 2021 by China National Medical Products Administration (国药准字H20213698). Furthermore, Ascletis has submitted marketing authorization applications for ritonavir (100 mg film-coated tablet) in 12 European countries (Germany, France, Ireland, the United Kingdom, Spain, Portugal, Italy, Belgium, Poland, Sweden, the Netherlands and Denmark) through its agent in Europe.
Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis, said, “With rapid global spread of the Omicron variant, there are more urgent needs for COVID-19 oral drugs. In addition to further expansion of annual ritonavir oral tablet production capacity, we are accelerating the development of ASC10 (targeting RdRp) and ASC11 (targeting 3CLpro), two novel oral drug candidates against COVID-19.”
About Ascletis
Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), a global platform covering the entire value chain…
[ad_2]
